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Introduction
The monoaminergic receptors, including the dopamine (DA)
receptors, belong to class A or the rhodopsin-like G-protein-
coupled receptor (GPCR) superfamily. The dopamine receptors
are classified into five types (D1–D5) and can be categorized
further into two main subfamilies: the D1- and D2-like recep-
tors.
[1] The D1-like receptors (D1 and D5) activate mainly adeny-
late cyclase, thus leading to an increase in intracellular cAMP
levels, whereas the D2-like receptors (D2,D 3, and D4) either in-
hibit adenylate cyclase or signal through other pathways.
[2]
Dopamine receptors in the central nervous system (CNS) play a
major role in the initiation and control of many vital brain
functions such as behavior, cognition, motor activity, learning,
and reward. Selective dopamine D2 and mixed D1/D2 receptor
agonists have been used in combination with l-DOPA in the
treatment of Parkinson’s disease since the early 1980s.
[3]
GPCRs contain seven transmembrane helices (TM1–7). The
signaling state of these receptors is associated with their active
conformations. Several studies have pointed to the key role
that conformational changes in TM3, TM5, and TM6 have in
GPCR activation.
[4–8] It has been suggested that the well-con-
served D(E)R
3.50Y
1 motif at the intracellular side of TM3 is im-
portant for receptor activation of monoaminergic GPCRs. Site-
directed mutagenesis studies on the a1b
[10] and b2
[7,11] adrener-
gic receptors, for example, have shown that an interaction be-
tween Arg
3.50 and the Glu
6.30 residue in TM6 restrains the move-
ment of TM6 and stabilizes the inactive state of the receptor.
This ionic lock is present in the crystal structures of inactive
bovine
[12] and squid
[13] rhodopsin receptors. The conformation-
al changes in TM6 upon activation are also supported by fluo-
rescence studies, which indicate an increased distance be-
tween TM3 and TM6.
[11,14] The ionic lock is not, however, pres-
ent in the inactive states of the recently solved b1 and b2 adre-
nergic receptor structures (adrb1 [PDB code: 2VT4], adrb2
[2RH1], respectively) or in the adenosine A2A (ad2a [PDB code:
3EML]) receptor structure.
[15–17] In the recently published dopa-
mine D3 receptor structure (drd3, 3PBL) by Chien et al.,
[18] the
ionic lock is present.
A combined modeling approach was used to identify structural
factors that underlie the structure–activity relationships (SARs)
of full dopamine D2 receptor agonists and structurally similar
inactive compounds. A 3D structural model of the dopamine
D2 receptor was constructed, with the agonist ( )-(R)-2-OH-
NPA present in the binding site during the modeling proce-
dure. The 3D model was evaluated and compared with our
previously published D2 agonist pharmacophore model. The
comparison revealed an inconsistency between the projected
hydrogen bonding feature (Ser-TM5) in the pharmacophore
model and the TM5 region in the structure model. A new re-
fined pharmacophore model was developed, guided by the
shape of the binding site in the receptor model and with less
emphasis on TM5 interactions. The combination of receptor
and pharmacophore modeling also identified the importance
of His393
6.55 for agonist binding. This convergent 3D pharma-
cophore and protein structure modeling strategy is considered
to be general and can be highly useful in less well-character-
ized systems to explore ligand–receptor interactions. The strat-
egy has the potential to identify weaknesses in the individual
models and thereby provides an opportunity to improve the
discriminating predictivity of both pharmacophore searches
and structure-based virtual screens.
[a] Dr. P. Svensson
NeuroSearch Sweden AB
Arvid Wallgrens Backe 20, 413 46 Gçteborg (Sweden)
E-mail: psv@neurosearch.com
[b] M. Malo, Prof. K. Luthman
Department of Chemistry, Medicinal Chemistry
University of Gothenburg, 412 96 Gçteborg (Sweden)
[c] Dr. L. Brive
Department of Biomedicine
University of Gothenburg, P.O. Box 440, 405 30 Gçteborg (Sweden)
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cmdc.201100545.
Re-use of this article is permitted in accordance with the Terms and
Conditions set out at http://onlinelibrary.wiley.com/journal/10.1002/
(ISSN)1860-7187/homepage/2452_onlineopen.html.
1 To facilitate a comparison between different GPCRs, we use the indexing
method introduced by Ballesteros and Weinstein,
[9] in which the most con-
served residue in every transmembrane (TM) helix is given the index number
50. For example, the Arg residue in the highly conserved DRY motif in the cy-
toplasmic end of TM3 is denoted Arg
3.50, the other residues in TM3 are then
indexed relative to this position, with the previous residue as Asp
3.49, and the
subsequent as Tyr
3.51. In addition, the absolute number of each residue in the
amino acid sequence is included. In Figure 2, the index number 50 for each
helix in the D2 receptor is highlighted.
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ing to a conformational change of the receptor.
[6,8,16,19–23] Ago-
nist binding initiates an outward movement of both TM5 and
TM6 at the cytoplasmic side, which in turn triggers the activa-
tion of the G protein.
[21–23] Site-selective fluorescence labeling
studies have also shown that the magnitude of fluorescence
changes upon agonist binding, which is indicative of a confor-
mational change induced by the agonist, correlates with intrin-
sic activity.
[8] Common structural features for dopamine and re-
lated monoaminergic receptor agonists are a basic amino func-
tion, hydrogen bond donor/acceptor groups, and an aromatic
ring system. How agonists bind to the D2 receptor and detailed
information regarding their typical key interactions have been
studied by several research groups with modeling,
[24–30] medici-
nal chemistry,
[31,32] and mutation studies.
[27,33–38]
Recent findings, however, reveal that monoaminergic GPCR
signaling is far more complicated than previously realized: re-
ceptor dimerization seems to play a crucial role in dopamine
D2 receptor (drd2) signaling.
[39] In addition, the receptors can
adopt several different activated conformations and can also
perform non-G-protein-mediated signaling via, for example, b-
arrestin pathways, resulting in a range of effects.
[40–42] Concepts
such as functional selectivity and biased ligands have emerged
and will most likely influence future pharmacological assay
design
[43,44] as well as drug discovery efforts directed toward
these targets.
[45] However, functional selectivity of agonists
should not be confused with agonist receptor-subtype selectiv-
ity, which is the focus of this study.
As mentioned above, Rasmussen et al.,
[46] together with
Cherezov, Rosenbaum, and co-workers,
[16] solved the 3D struc-
ture of the human b2 adrenergic receptor (adrb2; PDB codes:
2R4S and 2RH1). The adrb2 structure, which most likely repre-
sents an inactive conformation of the receptor, has the inverse
agonist carazolol bound.
[23] Since publication of the adrb2 crys-
tal structures, several other GPCRs have been crystallized such
as the human dopamine D3 receptor,
[18] the A2A adenosine re-
ceptor,
[47] and the turkey adrenergic receptor b1,
[15] together
with two crystal structures of native bovine opsin.
[48,49] These
opsin structures do not include ligands, but they were crystal-
lized under conditions that govern an activated conformation
of the receptor. Therefore, the structures contain some of the
features often recognized as typical for an active GPCR confor-
mation. For example, an extension of the cytoplasmic end of
TM5, an outward tilt of TM6 resulting in a pairing of the cyto-
plasmic ends of TM5 and TM6, and conformational changes in
the highly conserved D(E)R
3.50Y and NP
7.50xxY motifs that form
a binding cavity for the G protein.
[47]
We recently published a selective dopamine D2 agonist phar-
macophore model.
[28] It contains pharmacophoric features that
are present in full agonists that could indicate specific key in-
teractions with the receptor. These features are: 1) the salt
bridge between the amino function in the ligand and an as-
partic acid residue in TM3, denoted Asp-TM3, 2) the hydrogen
bond(s) from the phenol group(s) to serine residues in TM5
(Ser-TM5), and 3) the aromatic system (Aro), which includes a
direction of the p-system for optimal face-to-edge p–p interac-
tions with hydrophobic residues in TM6.
[28]
In the present study we developed dopamine D2 receptor
models to gain a better insight into agonist binding and the
reasons behind the selectivity between full agonists and struc-
turally similar inactive compounds. We included a more struc-
turally diverse set of ligands (Figure 1) than those used in pre-
viously published studies. The focus in this study is characteri-
zation of the agonist binding site using a combination of 3D
pharmacophore modeling and comparative (homology) mod-
eling of the dopamine D2 receptor, guided by available pub-
lished data. A dopamine D2 receptor homology model with all
loops except the third intracellular loop (IC3) was built. The ho-
mology model was further compared with and modified ac-
cording to our dopamine D2 agonist pharmacophore model.
[28]
The similarities and differences between the models were
analyzed in detail with regards to experimental data on ago-
nist affinity, efficacy, and effects of binding site mutations. De-
viations between the geometries of the D2 homology model
and the pharmacophore model were used to refine the phar-
macophore model with respect to the shape of the receptor
binding pocket.
Important amino acids for D2 agonist binding
Several interactions between the dopamine D2 receptor (drd2)
and its ligands have been verified experimentally by mutation
studies. For example, the aspartic acid residue (Asp114
3.32)i n
TM3 forms a salt bridge with the basic nitrogen atom of the li-
gands,
[26,38] and a cluster of serine residues in TM5 (Ser193
5.42,
Ser194
5.43, and Ser197
5.46) contribute to the binding of the cate-
chol moiety present in many agonists.
[33,36,37] However, Cox
et al.
[36] have shown that Ser193
5.42 is most important for bind-
ing of catechol-containing full agonists, whereas the frequently
used pyrazole-containing D2 receptor agonist quinpirole (7,
Figure 1) is not as sensitive for mutations at this position. Dop-
amine and the partial receptor agonist DHX showed no detect-
able agonist activity if Ser194
5.43 was replaced by alanine.
[33,36]
Wiens et al.
[33] also demonstrated that a Ser193
5.42!Ala muta-
tion does not affect the intrinsic activity of the full agonists (R)-
NPA and quinpirole, for example, whereas the efficacy of DHX
is drastically reduced. The binding affinity for all agonists was,
however, negatively affected by the Ser193
5.42!Ala and
Ser194
5.43!Ala mutations.
[33]
TM6 contains a cluster of hydrophobic amino acids that are
involved in agonist binding and in the activation of the GPCRs.
In particular, Phe390
6.52 is important for direct binding of the
catechol or corresponding aromatic rings in agonists,
[34,50]
while Phe389
6.51 has been suggested to interact with the posi-
tively charged basic nitrogen atom of the ligands.
[50] In binding
studies, Lundstrçm et al.
[51] have shown that a mutation of a
histidine residue located in TM6 in the D3 receptor
(His349
6.55!Leu) affects binding of dopamine, but not binding
of 7-OH-DPAT. In a D2 receptor mutation study performed by
Gmeiner and colleagues, both (R)-7-OH-DPAT and dopamine
were affected if His393
6.55 was replaced with an alanine resi-
due. Dopamine was the most sensitive of the two to this mu-
tation.
[35] The latter study also included quinpirole binding
data, and showed that the affinity of quinpirole for D2high (the
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in the mutated receptor. However, the efficacies were unaffect-
ed.
[35] In mutation studies, the corresponding amino acid in
adrb2 (Asn
6.55) has also been shown to be important for bind-
ing of full agonists, whereas partial agonists were only moder-
ately affected by an Asn
6.55!Leu mutation.
[52]
The second extracellular loop (EC2), which lines the binding
site crevice, is also important for agonist interaction and recep-
tor activation.
[53,54] All monoaminergic GPCRs have a disulfide
bridge (EC2-SS-TM3) that connects a cysteine residue in EC2
(Cys182 in drd2) with a cysteine in TM3 (Cys107
3.25 in drd2),
which thereby constrains the loop on top of the crevice. In the
muscarinic acetylcholine receptor, disruption of this disulfide
bond dramatically disrupts ligand binding.
[55] In addition, Noda
et al.
[56] showed that removal of EC2-SS-TM3 destabilizes the
high-affinity state of adrb2. Furthermore, by using the substi-
tuted-cysteine accessibility method (SCAM), Shi and Javitch
have shown that Ile184 and Asn186 located in EC2 in drd2
contribute to the binding site crevice, and are therefore avail-
able for direct ligand interactions.
[54] In the dopamine D3 recep-
tor (drd3) structure (3PBL), the corresponding asparagine resi-
due (Asn185) was shown to be directed toward TM4 and not
toward the binding crevice, as for drd2.
[54] Of all GPCRs, drd3
shares the highest sequence identity with drd2 (78%)
[18] and
therefore might be expected to be the most suitable template
for homology modeling of drd2. However, we do not consider
this to be the case in modeling D2 agonist–receptor interac-
tions because the drd3 structure is crystallized with the antag-
onist eticlopride present in the binding pocket. Eticlopride
binds closer to the extracellular side than carazolol does in
Figure 1. Selected D2 receptor full agonists 1–13a, partial agonists 8b, 10b, 14, 15a and DHX, and structurally related inactives 3b, 4b, 6b, 12b, and 15b–
21. For a more detailed account of the set, see reference [28].
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with Phe
6.52, an interaction that is crucial for agonist bind-
ing.
[34,50] In homology modeling, the template structure of con-
served amino acids in the two sequences will be enforced on
the model of the target protein (see below) and therefore a re-
ceptor structure with high homology but in a different confor-
mational state can be less suitable as a template than a struc-
ture with lower sequence homology. Therefore, in the present
study we chose the adrb2 structure (2RH1) as the template in
the homology modeling procedure; 2RH1 has a resolution of
2.4  , which is the highest resolution of all crystal structures of
monoaminergic GPCRs obtained so far. The main difference be-
tween the 2RH1 structure and the true receptor structure is
that the third intracellular loop (IC3) had to be replaced with
T4 lysozyme (T4L) in order to stabilize the receptor for crystalli-
zation. The D2 receptor model was built with a D2 receptor ag-
onist present to induce an active-state binding site conforma-
tion. By combining the pharmacophore and receptor modeling
approach (using all available SAR, mutational, and structural in-
formation) we aim at gaining a deeper understanding of the
features that govern D2 receptor agonism.
Results and Discussion
Sequence alignment
An initial sequence alignment between the human adrenergic
b2 receptor (adrb2, 2RH1
2) and drd2 was performed using Clus-
tal W (version 2.0.10).
[57] The program produced a correct align-
ment for the first five helices, but not for TM6 and TM7. The re-
moval of IC3 from both sequences, which is considerably
longer in drd2 than in adrb2, allowed a satisfactory alignment
of all seven helical regions. The Clustal W alignment obtained
initially (see figure 1 in the Supporting Information) was
checked carefully in the non-conserved positions close to the
binding site and in the loop regions.
Manual adjustments in some parts of the sequence align-
ments were made with the purpose of improving the final ho-
mology model (Figure 2). The adjustments in the initial align-
ment were:
TM4: The sequence LLTKN in adrb2 was moved to fill a gap at
the N terminus of TM4, and the sequence C
4.58PLLF in
drd2 was moved to fill a gap between Ser
4.57 and Cys
4.58.
EC2: The sequence DQNECIIAN in drd2 was aligned with
amino acids located in the short helix present in adrb2
(EC2 helix, Figures 2 and 3). The target sequence has a
considerably shorter loop than the template (11 resi-
dues shorter). QNECIIAN were moved toward the N ter-
minus of TM4. The cysteine bridge EC2-SS-TM3 in drd2
was aligned with the corresponding cysteine bridge in
the template sequence. The EC2 residues Asn186 and
Ile184 in drd2 are important for ligand interactions,
[54]
and were therefore aligned with the corresponding Thr
and Phe residues in adrb2, which point downward to
the binding crevice.
IC3: The lysozyme insert was removed from adrb2, as was
the corresponding sequence in drd2.
TM7: The sequence CRS in adrb2 was moved to remove a
gap at the C terminus of the helix.
The sequence similarity between adrb2 and drd2 in the
manually adjusted alignment was 35% in total, 41% in the
helix regions, and 57% in the binding pocket. The binding
pocket is defined by amino acids within 3.5   from the D2 re-
ceptor agonist ( )-(R)-2-OH-NPA,
[32] which was used as environ-
ment
3 for induced fit during the homology modeling procedure.
Figure 2. The final sequence alignment of the human adrenergic b2 receptor (adrb2, 2RH1) and the human dopamine D2 receptor (drd2). The adrb2 (DSC)
bars indicate the transmembrane (TM) helix regions and the second extracellular loop helix (EC2 Helix) in the adrb2 structure. The amino acid sequence for ly-
sozyme in adrb2 and the third intracellular loop (IC3) in drd2 between TM5 and TM6 were excised. This is marked with a dashed line. The ring at the N termi-
nus of TM5 indicates the gap where the alanine residue was introduced to prevent Pro188
5.37 from being forced into the second extracellular loop (EC2; see
text). Amino acids marked in dark blue indicate fully conserved positions, medium blue residues have highly similar physicochemical character, and light blue
residues have less similar physicochemical character. The conserved cysteine bridge between TM3 and EC2 (EC2-SS-TM3) is indicated. The most conserved res-
idue in each helix is marked with the index 50.
2 One amino acid in the second extracellular loop of the b2 structure (2RH1)
differs relative to the wild-type receptor (Asn187Glu).
3 The environment atoms (e.g., ligand structures and/or structural water mole-
cules) are specified by the user and are included in the energy tests and mini-
mization stages during the homology modeling procedure.
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In the applied homology modeling procedure,
4 all heavy
atoms of strictly conserved residues in the target model inher-
ited their coordinates from the template. In the non-conserved
region the backbone geometry was copied. Conserved disul-
fide bonds were also copied to the model. Non-aligned regions
where the backbone coordinates were indefinite (i.e., regions
with deletions or insertions that are often located in loops)
were modeled based on fragments from high-resolution re-
gions of proteins in the RCSB Protein Data Bank
[59] (PDB).
[60]
The fragment search included a clustering algorithm based on
similarity of anchoring regions (each fragment consists of two
anchor regions and a central region). The fragments were
anchored to the conserved and initially modeled residues, and
a contact energy function was used to rank fragment candi-
dates, taking into account all atoms from conserved residues
and any specified environment atoms. The coordinates for the
chosen fragment structure were then copied to the homology
model. Once all the loop structures had been selected, the
side chains of the non-conserved residues were constructed.
Side chains were modeled from data assembled from an ex-
tensive rotamer library generated by systematic clustering of
high-resolution structures in the PDB. A deterministic proce-
dure based on unary quadratic optimization (UQO) was then
run to select an optimal packing.
[61] After all backbone seg-
ments and side chain conformations had been chosen for an
intermediate model, hydrogen atoms were added to complete
the valence requirements. The model was then submitted to a
series of energy minimizations before the final preparation of
the model was scored and written to an output database. The
number of main chain models to be generated was specified
in the program. In addition, structures with variations in the
side chain conformations were generated for each model;
however, the first side chain model was always built with the
UQO procedure. The force field used for the receptor modeling
in this study was Amber99
[62] with R-field solvation, as imple-
mented in the MOE software.
[58]
The cysteine bridge between Cys182 and Cys107
3.25 (EC2-SS-
TM3) in drd2 makes the N-terminal stretch of the EC2 loop
more constrained than in the template structure (adrb2) due
to the shorter sequence between the cysteine bridge and TM5
in drd2 (Figure 2). In an initial homology model, Pro187
5.36 at
the N terminus of TM5 was positioned in the loop (EC2), al-
though prolines are known to introduce kinks or terminate
helices. This is a consequence of the homology modeling
method being so highly governed by the template structure.
To prevent Pro187
5.36 from being forced into the loop region,
we used a novel strategy based on the introduction of an addi-
tional alanine residue just before the proline, which allowed
proline to start the helix instead (marked with a green ring in
Figure 2). The introduced alanine residue was then manually
deleted, which left a gap in the structure, but a counterclock-
wise rotation around the center of the lower part of TM5 (after
the proline kink) shortened the distance between Pro187
5.36
and Asn186 in EC2. These two amino acids were reconnected,
and a restrained energy minimization was performed in which
everything was fixed except the N terminus of TM5, the EC2
with the cysteine bridge, and the C terminus of TM3. In the re-
sulting structure, TM5 begins with Pro187
5.36 and becomes
slightly tilted inward compared with the initial homology
model, which was highly similar to the template structure in
that region. A structural superposition of the final model and
the template is shown in Figure 3. In the final model the bulky
residues Ile184 and Asn186 in EC2 are directed downward into
the binding pocket, as suggested by Shi and Javitch,
[54] which
may, therefore, influence ligand binding.
To gather more information regarding the structure of the
agonist binding site in drd2 and the key interactions in agonist
binding, the D2 receptor agonist ( )-(R)-2-OH-NPA
[32] was pres-
ent as environment in the binding site during the homology
modeling procedure. ( )-(R)-2-OH-NPA is a structurally rigid full
D2 agonist that contains not only the typical D2 agonist func-
tional groups, such as a propyl-substituted basic nitrogen
atom and a catechol moiety, but also a hydroxy group at the
2-position (Figure 4). This hydroxy group may interact with
Asn186 in EC2 via hydrogen bonding, which would stabilize
ligand binding and steer the Asn186 side chain toward the
binding pocket.
[54]
During the modeling procedure, 20 homology models were
generated independently, and for each model all side chain
conformations were sampled three times. The backbone struc-
ture of the models varied mainly in EC2 and IC2, while helical
regions showed very little variation. The side chain conforma-
tions differed mainly in the two loop regions in the different
homology models. Minor differences were also observed in
some helical regions where there was more than one optimal
packing solution. The structural quality of the 60 homology
models obtained was inspected carefully. The focus was direct-
ed at the agonist binding site region and the important inter-
acting amino acids (Figure 4). The following protein structural
properties were evaluated: 1) the bond lengths, angles and di-
hedrals of the protein backbone; 2) Ramachandran plots of f–
y dihedrals (general, glycine, proline, and pre-proline; for ex-
planations, see figure 2 in the Supporting Information); 3) side
chain rotamer quality; and 4) non-bonded amino acid steric
clashes. To refine the model, hydrogen atoms were added to
the ligand, and the ionization and tautomeric states of the
ligand–receptor complex were determined. The complex was
refined further by energy minimization with ( )-(R)-2-OH-NPA
present in the binding site with motion restrictions on all
heavy atoms. This step was followed by an unconstrained
energy minimization. The overall geometry of this model was
investigated and evaluated further with the Procheck pro-
gram.
[63] When excluding glycines and prolines, 199 residues
(83%) belonged to the most favored region of the Ramachan-
dran map, 37 (16%) in the allowed, and three (1%) in the gen-
erously allowed region (according to Procheck). No residues
belonged to disallowed regions. All main chain and side chain
geometries were designated to the “better” class, except for f
torsions of Asn176 and Cys182 in the EC2, which were 1488
4 The modeling was performed by using tools implemented in the MOE soft-
ware package.
[58]
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tween the receptor and the ligand, of which four included hy-
drogen atoms involved in hydrogen bonds. Close contacts are
defined as pairs of non-bonded atoms within a distance of
2.6   from one another.
The selected D2 agonist induced receptor model
The final model has an RMSD of 2.1   in relation to the tem-
plate structure for all Ca atoms and 1.5   for Ca atoms of the
transmembrane region. The volume of the orthosteric binding
pocket is 371  
3. High structural similarity was observed for
the backbone region except in the EC2, where the loop in the
template adopts a helical structure (Figures 2 and 3). In addi-
tion, TM5 and TM6 are gently tilted inward at the extracellular
side, slightly sealing the binding pocket (Figure 3). According
to Mobarec et al. the TM regions of GPCRs differ more toward
the extracellular side.
[64] The binding site amino acids in drd2
participate in the key interactions with the agonist ( )-(R)-2-
OH-NPA, described in detail above. The distance from the
oxygen atom in the C10 hydroxy group in 2-OH-NPA (the para
position in its dopamine substructure) to the oxygen atom of
the hydroxy group in Ser193
5.42 is 3.0  , and the O-H-
O(Ser193
5.42) angle is 1648 (Figure 4). The oxygen atom at the
corresponding meta position interacts with the imidazole NH
group in His393
6.55 with a distance of 2.9   between the heavy
atoms and an O-H-N(His393
6.55) angle of 1578. The other nitro-
gen atom of the imidazole ring in His393
6.55 interacts with the
phenolic function in Tyr408
7.43 (Figure 5). The oxygen atom in
Ser197
5.46 is 4.9   away from the oxygen of the meta-hydroxy
group in 2-OH-(R)-NPA, and
therefore does not interact di-
rectly with the ligand, but in-
stead forms a hydrogen bond
with Ser193
5.42. This is in agree-
ment with mutation studies
[33]
performed by Wiens and co-
workers in which the affinity and
efficacy of (R)-NPA toward drd2
were only slightly affected by
the Ser197
5.46!Ala mutation.
Mutation of Ser193
5.42 or
Ser194
5.43, however, significantly
decreased the receptor affinity
for several agonists. The hydroxy
group at the 2-position of ( )-
(R)-2-OH-NPA interacts with the
carbonyl oxygen and the NH
group in the amide moiety of
Asn186 located in EC2 (Figure 4
and 5).
The distance and angles be-
tween the pairs of heavy atoms
Figure 4. Schematic view of the interactions between the full agonist (R)-2-
OH-NPA and the dopamine D2 receptor homology model. The typical cate-
cholamine agonist–receptor key interactions with Asp114
3.32 Ser193
5.42 and
Phe390
6.52 are shown, together with the interactions between the hydroxy
group at the 11-position in (R)-2-OH-NPA and His393
6.55. In addition, the hy-
droxy group at the 2-position participates in a hydrogen bond with Asn186
in EC2, and Phe389
6.51 forms a p–p interaction with the monohydroxylated
phenyl group of the ligand. The characteristic propyl/allyl pocket is also indi-
cated, located between the residues Val83
2.53, Cys118
3.36, Trp386
6.48, and
Tyr416
7.43. Amino acids in purple are polar, while green residues are hydro-
phobic. The blue shades indicate ligand–receptor solvent accessibility.
Figure 3. Two orthogonal views of the dopamine D2 receptor (drd2) homology model (yellow) with the full ago-
nist (R)-2-OH-NPA present in the binding site, and the structure of the adrenergic b2 receptor (adrb2; 2RH1) in
red. Some interacting amino acids of drd2 are included together with the corresponding residues in adrb2. These
structures differ particularly in the second extracellular loop (EC2), but also in the upper part of transmembrane
helix 5 (TM5) and TM6, where important interacting amino acids are positioned.
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O=(Asn186), respectively. The basic nitrogen atom of the
ligand forms a hydrogen bond stabilized salt bridge with
Asp114
3.32, the distance between the heavy atoms is 2.7  , and
the N-H-O=(Asp114
3.32) angle is 1718. The characteristic hydro-
phobic N-alkyl/propyl pocket
[65] in the D2 receptor is also pres-
ent in the model and is localized between the residues
Val83
2.53, Cys118
3.36, Trp386
6.48, Thr412
7.39, and Tyr416
7.43,a s
shown schematically in Figure 4 and partly in Figure 5, and in
Supporting Information figure 3. The side chain methyl group
of Thr412
7.39 points toward the propyl chain of ( )-(R)-2-OH-
NPA, while its hydroxy group interacts with the backbone car-
bonyl of Tyr408
7.43, which in turn may further interact and sta-
bilize the position of the His393
6.55 residue. Tyr416
7.35 forms a
hydrogen bond with Asp114
3.32 and stabilizes the position of
the aspartic acid, which further interacts with the basic nitro-
gen atom of the ligand (Figures 5 and 6). In addition,
Phe390
6.52, which has been shown to be important for agonist
binding,
[50] forms a face-to-edge p–p interaction with the
ligand (Figures 4, 5, and 6, and figure 3 in the Supporting Infor-
mation).
McRobb et al.
[66] recently published several GPCR homology
models based on the adrb2 structure (2RH1), including the D2
receptor. Their intention was to enrich high-throughput
screening (HTS) results for receptor antagonists. Although we
focus on agonist binding herein, we have compared our
model with their D2 model to identify differences. The two
models differ significantly in the orthosteric binding site. The
distance between one of the oxygen atoms in Asp114
3.32 and
the oxygen in the hydroxy group of Ser193
5.42 is 10.2   in the
McRobb model and 9.1   in ours, which is in accordance with
the fact that we are modeling an agonist-bound conformation
of the receptor, whereas they are not. Warne et al. have shown
a similar distance difference in adrenergic b1 receptor crystal
Figure 5. Two orthogonal views of the recently published selective dopamine D2 agonist pharmacophore model
[28] superimposed into the D2 homology
model. Transmembrane helix 6 (TM6) is not shown on the side view (right), but the side chains of the interacting amino acids Phe389
6.51, Phe390
6.52, and
Trp386
6.48 are still included. The positioning of the anion feature (red) superimposes well with the aspartic acid Asp114
3.32, as well as the position and direction
of the aromatic system (orange), while the hydrogen bonding feature, together with the excluded volumes, mismatch with the receptor.
Figure 6. Top view of the new refined pharmacophore model based on the agonist-induced dopamine D2 homology model, with (R)-2-OH-NPA present in the
binding site (left). A side view of the D2 homology mode with the new refined pharmacophore model is shown at right. TM6, the hydrogen atoms of the in-
teracting amino acids, and the corresponding excluded volumes are not shown. The conformation of (R)-2-OH-NPA is taken from the ligand–receptor homolo-
gy model complex, whereas the relative positions of the pharmacophore features are tuned to generate the best hit rate.
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[22] They found that the length of the binding
pocket, defined as the distance between Ser
5.42 and Asn
7.39,i s
contracted by 1   with an agonist bound relative to when an
antagonist is bound. The geometry of EC2 also varies signifi-
cantly; both Ile184 and Asn186 point toward the binding crev-
ice in our model, whereas they point toward TM4 in the
McRobb model.
Comparison of the dopamine D2 receptor model and the
selective D2 agonist pharmacophore model
The recently published selective D2 agonist pharmacophore
model
[28] was superimposed into the generated structure
model of the D2 receptor to compare interacting amino acids
with the pharmacophoric features and excluded volumes. The
geometry of the feature arrangement in the pharmacophore is
in good agreement with the structure model, with the excep-
tion of the Ser-TM5 feature, which did not coincide with the
serine residues but was instead located more toward the extra-
cellular side close to Val190
5.39 (Figure 5). There were also dif-
ferences in the localization of excluded volumes compared
with the shape of the binding site. There could be several rea-
sons for these types of mismatches, such as technical limita-
tions of the modeling methodologies used or lack of experi-
mental information when building both types of models. One
reason is that the pharmacophore query tool applied has an-
gular limitations for how hydrogen bond acceptors and donors
may interact with extended pharmacophore features.
[67] The
OH groups in the cathecol or phenol functions that are present
in the majority of the D2 ligands could only hit an extended
donor or acceptor feature at two distinct positions separated
by 1208 in the plane of the aromatic ring. This must be regard-
ed as a limitation, as reasonably strong hydrogen bonds could
most certainly be formed at directions that deviate from these
optima. In the drd2 model Ser193
5.42 is located in a position
available for hydrogen bonding to the agonist, but rotation
out of the ring plane of the phenol or catechol hydroxy
groups is then required. This type of out-of-plane rotation is
not captured in the pharmacophore development, as all active
ligands with phenolic hydroxy groups prefer an in-plane con-
formation in the absence of the binding site environment. One
published example of such an out-of-plane hydrogen bond in-
teraction is shown in the crystal structure of adrenaline, in
which the meta-hydroxy group in the catechol moiety is rotat-
ed 718 relative to the aromatic ring to form a hydrogen bond
with a structural water molecule.
[68] A second reason for the
mismatch between the models in the TM5 region may be that
water-mediated hydrogen bonds between the serine residues
and the D2 ligands in the receptor model are not considered. A
third reason could be that the dynamic aspect of a functional
receptor is not modeled by the homology model but may be
represented in the set of active and inactive ligands used in
the pharmacophore modeling (i.e., there could be a better
match with functionally important alternative receptor confor-
mations different from the snapshot conformation found in
the crystal). Other reasons could be possible errors introduced
by structural differences between the template and target
structures not picked up by the homology modeling proce-
dure, and structural artifacts in the template caused by protein
engineering or crystal packing.
On the other hand, it has been shown in several studies that
the serines in TM5 are of varied importance for agonist binding
in the D2 receptor.
[33,36] For example, Payne et al.
[31] showed
that the non-hydroxylated dipropylaminotetralin derivative (S)-
DPAT is a full D2 receptor agonist, but with low affinity. The
same study included both enantiomeric forms of a number of
DPAT analogues in which hydroxy groups were differently posi-
tioned, resulting in varied affinities and efficacies. These deriva-
tives can thus provide a deeper understanding of the involve-
ment of the serine residues in agonist binding to the D2 recep-
tor. A similar set of agonist ligands was used by Sahlholm
et al.
[69] who used voltage-sensitivity measurements to investi-
gate the importance of hydrogen bonding interactions to the
serines. It was proposed that the hydrogen bonding to the ser-
ines was important for flexible ligands (e.g., meta-tyramine) to
allow a proper interaction between the aromatic ring of the
ligand and the aromatic cluster in TM6. In the DPAT series,
however, Sahlholm et al. suggested that the rigidity of the ring
system results in a tight interaction of the aromatic ring with-
out the need for additional hydrogen bonding interactions.
The hydrogen bonds to the serines are not considered to be
crucial for agonism but that they enhance the affinity. The au-
thors also suggest that the more constrained binding modes
of the full DPAT agonists and dopamine make them voltage
sensitive due to a voltage-induced rotation of TM6 upon re-
ceptor activation.
[69]
Refinement of the D2 pharmacophore model
As the positioning of the Ser-TM5 feature in the pharmaco-
phore model differed significantly relative to the drd2 homolo-
gy model (Figure 5), we decided to move this feature to a posi-
tion more consistent with the Ser193
5.42 position. The new Ser-
TM5 feature was positioned deeper in the binding crevice
based on projected hydrogen bond annotation points generat-
ed from the pharmacophore hits of low-energy conformers of
the full D2 receptor agonists. One argument for why TM5 hy-
drogen bond interactions may not be crucial for D2 receptor
agonism is that the full agonist (S)-DPAT has no aromatic sub-
stituents or heteroatoms in that region. The hydrogen bond in-
teractions to the serines in TM5 may, however, contribute to
agonist affinity, so the Ser-TM5 feature was therefore defined
as optional in the new pharmacophore. The other features in
the pharmacophore model were kept as essential, which
means that they must be matched. In addition, the positioning
of the excluded volumes was arranged based on the shape of
the agonist binding pocket. For example, excluded volumes
were introduced to cover hydrogen atoms in amino acids lo-
cated within 3   of ( )-(R)-2-OH-NPA, including those involved
in hydrogen bonding with the ligand. The initial radii of the ex-
cluded volumes were selected from the van der Waals radii
(vdWr) proposed by Bondi,
[70] (i.e., 1.2   for aliphatic and 1.0  
for aromatic hydrogen atoms). The vdWr for hydroxy and
amine hydrogen atoms are not defined by Bondi, but were set
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the excluded volumes were tuned manually until the pharma-
cophore model was sufficiently selective between actives and
inactives. The final radii were 2.0 for aliphatic and 1.8   for aro-
matic hydrogens. We also introduced excluded volumes (radii
2.5  ) positioned at the center of mass of the aromatic rings to
avoid clashes between perpendicularly positioned aromatic
ring systems in the receptor and the ligand (Figure 6).
The alignment of the feature part of the pharmacophore
model in relation to the set of new excluded volumes derived
from the receptor model was tuned manually and evaluated
by the hit rate of the ligand training set. The alignment that re-
sulted in the best discrimination between actives and inactives
was selected. The new refined pharmacophore model was
screened against two conformational ensembles of D2 ligands
(structures shown in Figure 1; for a full account of the set, see
reference [28]) generated with both MOE
[58] (mmffs)
[71] and
MacroModel
[72] (OPLS)
[73] software and Born solvation (water).
The results of the initial screen were good and compared well
with those obtained using the previously published pharmaco-
phore model,
[28] despite the fact that the hit criterion for the
Ser-TM5 feature was changed from essential to optional
(Table 1). The excluded oxygen feature (exclO) was kept from
the old D2 agonist pharmacophore model to prevent doxanthr-
ine, the inactive DHX analogue, from fitting into the model.
Unlike DHX, doxanthrine has an ether function that is directed
toward a hydrophobic environment in the receptor. To gain a
deeper understanding of the properties that govern agonist af-
finity and efficacy, we investigated in detail how the different
ligands that fit the new pharmacophore model interact with
the receptor binding site. The best hit of each compound in
the pharmacophore model was evaluated by measuring the
hydrogen bond distances and angles between the ligand and
the amino acids Ser193
5.42 and His393
6.55 (Table 1).
[33,35,36] The
optimal distance for hydrogen bonding is ~2.8   between the
heavy atoms, but because the receptor is flexible we consider
distances between 2.4 and 3.8   to be acceptable. The angle
between the heavy atom and the hydrogen of the ligand to
oxygen in the interacting amino acid (N/O-H-O(Ser193
5.42) and
N/O-H-N(His393
6.55)) should ideally be 180 408 (Table 1).
Results of the pharmacophore model search
The same set of D2 receptor ligands (13 full agonists, five par-
tial agonists, and 12 structurally similar inactives; Figure 1)
used in the previously published pharmacophore modeling
study
[28] were screened against the new pharmacophore model
based on the dopamine D2 receptor model. All full agonists
except (R)-3-PPP and A70108 (11/13 OPLS generated set of li-
gands), and all but one ((S)-3-PPP) of the partial agonists (4/5)
fit into the pharmacophore model. In addition, the model ex-
cluded all but one of the inactives ((S)-7-OH-DPAT) (1/12)
(Table 1). The main reason that 3-PPP did not fit the model is
the perpendicular orientation between the piperidine and
phenol rings in low-energy conformations. A70108, which has
a single bonded phenyl ring attached to an isochromane scaf-
fold, shows a similar orientation of the ring systems (Figure 1).
All three compounds show relatively low affinity for the D2 re-
ceptor, and this might be explained by the conformational
changes required for binding, as suggested by Liljefors and
Wikstrom, for the 3-PPP enantiomers.
[65] For further evaluation
we screened the pharmacophore model against a set of
MMFF(s)-generated conformations, which resulted in the loss
of one additional active ligand ((R,R)-PHNO) (10/13).
Some of the full and partial agonists that fit into the phar-
macophore model did not fulfill the specified criteria regarding
hydrogen bond distances and angles. All full agonist hits had
at least one proper hydrogen bond except for (S)-DPAT, which
lacks the hydrogen bonding substituents, and sumanirole,
which may form a hydrogen bond with a distance of 4.0   and
an angle of 1288 with the Asn186 residue in the EC2 instead
(see figure 4 in the Supporting Information). All hits of the par-
tial agonists had one proper hydrogen bonding interaction
except (S)-6-OH-DPAT, which may indicate different binding
modes. The distance from the oxygen atom in the hydroxy
group of (S)-6-OH-DPAT to the oxygen in Ser193
5.42 is 4.0  
(1798), which is longer than what is optimal for a hydrogen
bond. Formation of a proper hydrogen bond may, however,
prevent a simultaneous interaction of (S)-6-OH-DPAT with
Phe390
6.52, which has been shown to be important for agonist
binding.
[34,50] The inactive ligand (S)-7-OH-DPAT fit into the
model, but was unable to make hydrogen bonding interac-
tions with His393
6.55 and Ser193
5.42. Several of the full agonists
such as (R)-NPA were oriented in a position in which hydrogen
bonds might be formed with both Ser193
5.42 and His393
6.55.
The partial agonist DHX interacted with His393
6.55 at a subopti-
mal distance and angle, but it can form hydrogen bonds to
Ser193
5.42 with both catechol hydroxy groups. DHX lacked the
efficacy for inhibition of adenylate cyclase via the Ser193!
Ala
5.42 mutated receptor, while the intrinsic activities remained
for (R)-NPA and the non-catecholamine agonists quinpirole and
(R)-7-OH-DPAT in the same mutated receptor.
[33]
The mutation may lead to a different binding mode for DHX
due to hydrogen bond formation between the meta-hydroxy
group and His393
6.55, causing a loss of the face-to-edge p–p in-
teraction with Phe390
6.52. In addition, DHX lacks the N-propyl
substituent, which has been shown to enhance D2 receptor ag-
onist binding affinity. Together, this mutation and an absence
of the propyl substituent in DHX may explain the decrease in
efficacy. The pyrazole-containing D2 receptor agonist quinpirole
is completely insensitive to the Ser193!Ala
5.42 mutation,
which could be explained by the orientation of the best phar-
macophore hit of quinpirole, where the pyrazole hydrogen is
unable to interact with any of the hydroxy groups in the clus-
ter of serine residues. Instead, quinpirole may form a hydrogen
bond to the backbone carbonyl of Ser193
5.42, with a distance
of 3.7   and an angle of 1528.
As mentioned above, quinpirole is sensitive to the
His393
6.55!Ala mutation, but the nitrogen atom of the pyra-
zole ring is not directly accessible for hydrogen bonding.
[35] Be-
cause the pyrazole is located closer to the aqueous extracellu-
lar side, there are most likely water molecules that may link
the ligand and His393
6.55 (Table 1). Another explanation for the
decreased affinity in the mutant is the loss of a hydrogen
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6.55 and Asn186 in EC2. The
quinpirole-induced movements of Asn186 and His393
6.55 are
shown in Figure 7 below and in figure 3 in the Supporting In-
formation. Asn186 moves toward TM6 and interacts with
His393
6.55, which in turn moves downward to interact with the
pyrazole nitrogen atom of quinpirole. Talipexole may also inter-
act in a similar way as quinpirole and form a hydrogen bond
from the amine to the backbone carbonyl oxygen of Ser193
5.42.
To evaluate the importance of the excluded volumes for dis-
criminating actives from inactives for the new pharmacophore
model we performed a test in which we removed the volumes
in the same manner as in our previous study.
[28] The new D2 re-
ceptor agonist pharmacophore model without excluded vol-
umes was screened against a conformational import-generated
ensemble of the D2 receptor ligands. The test model excluded
only one partial agonist ((S)-3-PPP), while all other ligands fit. If
the hit priority of the TM5 feature was changed to be essen-
tial, the test model succeeded in discriminating two more inac-
tives ((S)-7-OH-DPAT and (S,S)-PHNO) and the full agonist (S)-
DPAT (because it lacks the phenolic hydroxy groups). The same
test was made earlier for the published D2 receptor pharmaco-
phore model
[28] (with an essential TM5 feature). In that test, all
Table 1. Comparison of the search results from the old and new D2 agonist pharmacophore models for two different ensembles of generated conforma-
tions.
New pharmacophore model Old pharmacophore model
Ligand MOE stochastic search
Born solvation
MMFF94(S)
[a]
MacroModel serial torsion search
GB/SA solvation OPLS2005
[b]
MOE stochastic search
Born solvation
MMFF94(S)
[a]
MacroModel serial
torsion search
GB/SA solvation
OPLS2005
[b]
DE
[c] RMSD
[d] #c/#h
[e] DE
[c] RMSD
[d] S193
d[ ](a[8])
[f]
H393
d[ ](a[8])
[g]
#c/#h
[e] DE
[c] RMSD
[d] #c/#h
[e] DE
[c] RMSD
[d] #c/#h
[e]
(R)-NPA (1)
[h] Full 0.0 0.26 12/3 0.6 0.22 m3.7(129)
p2.4(163)
3.6(157) 21/11 0.0 0.59 12/6 0.0 0.45 21/19
Talipexole (2)
[h] Full 0.0 0.43 44/28 0.0 0.43 2.4(171) 4.1(151) 28/15 0.0 0.54 44/22 0.0 0.51 28/14
Sumanirole (3a) Full 0.0 0.26 5/1 0.3 0.32 3/1 0.0 0.32 5/2 0.0 0.23 3/2
(R,R)-PHNO (4a) Full 0.0 0.3 6/1 1.3 0.30 2.7(144) 4.6(152) 12/6 0.0 0.51 6/4 0.0 0.50 12/12
nPr-DHX (5)
[h] Full 0.4 0.39 3/1 0.0 0.36 m3.0(147)
p2.9(139)
4.5(144) 57/6 0.4 0.47 3/1 0.0 0.44 57/24
( )-(3S,9R)-6a
[h] Full 0.0 0.25 5/3 0.0 0.25 3.7(128) 3.6(158) 12/6 0.0 0.53 5/5 0.0 0.54 12/12
Quinpirole (7)
[h] Full 0.1 0.26 5/1 1,1 0.21 4.4(150) 9/4 0.0 0.38 5/5 0.0 0.36 9/7
(S)-5-OH-DPAT (8a) Full 1.7 0.26 78/12 2.2 0.26 3.7(128) 3.6(164) 140/11 1.7 0.57 78/21 2.1 0.57 140/30
(S)-DPAT (9) Full 1.7 0.27 79/12 2.2 0.27 79/6
(R)-3-PPP (10a)
[h] Full 26/0 43/0 3.5 0.68 26/3 43/0
Apomorphine (11)
[h] Full 0.0 0.19 2/1 0.0 0.21 2.4(164) 3.6(157) 4/4 0.0 0.56 2/1 0.0 0.47 4/4
Dopamine (12) Full 0.0 0.57 8/4 0.0 0.58 m3.8(137)
p2.6(145)
m3.8(167) 20/12 0.0 0.66 8/3 0.0 0.61 20/6
A70108 (13a) Full 6/0 10/0 2.2 0.57 6/2 2.8 0.58 10/1
(R)-5-OH-DPAT (8b) Partial 0.0 0.67 75/13 2.3 0.66 3.5(132) 3.7(158) 140/14 75/0 140/0
(S)-3-PPP (10b)
[h] Partial 18/0 54/0 18/0 54/0
(S)-6-OH-DPAT (14) Partial 1.7 0.26 82/14 2.2 0.27 4.0(179) 154/14 1.7 0.53 82/22 2.1 0.54 154/34
(R)-7-OH-DPAT (15) Partial 0.0 0.67 84/13 2.2 0.27 2.6(148) 152/16 1.8 0.65 84/16 2.1 0.63 152/28
DHX Partial 0.0 0.32 m2.9(150)
p2.8(143)
(S)-Sumanirole (3b) Inactive 5/0 3/0 5/0 1.5 0.62 3/1
(S,S)-PHNO (4b)
[h] Inactive 6/0 16/0 6/0 16/0
(+)-(3R,9S)-6b
[h] Inactive 5/0 12/0 5/0 12/0
(S)-7-OH-DPAT (15b) Inactive 1.7 0.67 79/12 2.8 0.25 3.8(128) 151/5 79/0 151/0
Doxanthrine (16) Inactive 2/0 16/0 2/0 16/0
A86929 (17) Inactive 11/0 48/0 11/0 0.0 0.64 48/23
A77636 (18a) Inactive 3/0 11/0 3/0 11/0
A77641 (18b) Inactive 3/0 11/0 3/0 11/0
A70360 (13b) Inactive 5/0 15/0 5/0 15/0
SKF38393 (19) Inactive 5/0 22/0 5/0 22/0
cis-DHX (20) Inactive 6/0 12/0 6/0 12/0
( )-DHX (21) Inactive 2/0 14/0 2/0 14/0
[a] The energy cutoff for conformations generated in MOE is 4 kcalmol
 1. [b] The energy cutoff for conformations generated in MacroModel is
16.7 kJmol
 1 (~4 kcalmol
 1). [c] The relative energy [kcalmol
 1] of the conformer that fit the pharmacophore model, related to the most stable conformer
in the ensemble. [d] Root of the mean square distance between the center of the pharmacophore features and their matching ligand annotation points.
[e] #c: number of conformations generated using the assigned method; #h: number of conformations that hit the pharmacophore model. [f] Hydrogen
bond distance and angle between heavy atoms of Ser193 of the receptor and the best hits in the new pharmacophore model (O H O). [g] Hydrogen
bond distance and angle between heavy atoms of His393 of the receptor and the best hits in the new pharmacophore model (HA H N). [f,g] The para
and meta positions of the hydroxy groups in the dopamine substructure are respectively indicated by p and m; values in boldface are just outside the per-
mitted values (2.4–3.8   and 180 408). [h] The tertiary amine is considered chiral, and two different configurations have been used in the modeling.
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partial agonists (2/4) and all but four inactives (8/12) fit into
the model. The discriminating ability of the new model, which
is constructed based on the shape of the binding pocket, de-
pends more on its excluded volumes than does the old phar-
macophore model.
In summary, there is a good agreement between the phar-
macophore and 3D structure models. However, differences in
the models that may indicate specific weaknesses in the meth-
ods and/or lack of information have been pointed out. There-
fore, the combination of ligand- and structure-based modeling
provides the possibility of cross-validating the models as well
as a handle on how to construct more accurate models.
Conclusions
In this study, a 3D structural model of the D2 receptor was de-
veloped. The previously published selective D2 agonist phar-
macophore
[28] model, consisting of a 3D arrangement of mo-
lecular features, projected intermolecular interaction features,
and excluded volumes, was aligned and compared with the re-
ceptor model. Furthermore, a new refined pharmacophore
model, guided by the shape of the binding site in the receptor
model, was developed. The pharmacophore and the protein
structure models were constructed based on distinctly differ-
ent sets of published experimental data, and are based on mu-
tually independent assumptions and approximations. This type
of combined approach helps to identify strengths and weak-
nesses in both strategies. The 3D model of the receptor
showed good geometric quality, and the typical D2 receptor
agonist key interactions with the receptor model were present.
The selective and potent D2 receptor agonist ( )-(R)-2-OH-NPA
was positioned in the binding site during the construction of
the receptor model and thereby induced a conformational
change of the receptor, where the binding site is shaped to ac-
commodate an agonist. Furthermore, other important amino
acids were also identified and validated based on structural in-
formation together with available binding and mutation data.
We discovered, for example, that in addition to the serine resi-
dues in TM5, His393
6.55 may also be highly important for the
hydrogen bonding of agonists. This was also supported by mu-
tation data.
[35] In addition, it was revealed from the comparison
of the 3D receptor model with the published D2 agonist phar-
macophore model, that one hydrogen bonding feature (Ser-
TM5) was incorrectly positioned; therefore, a repositioning was
performed to obtain a better agreement with the 3D model.
The hit criterion for the Ser-TM5 feature was also redefined
from being essential for hits to being optional. The hit rate of
the pharmacophore search was retained, which indicates that
the agonist selectivity does not depend on TM5 hydrogen
bonding. However, hydrogen bonding to TM5 may still en-
hance the binding affinity of the agonists. Careful modeling of
the loop regions was carried out, especially of the second ex-
tracellular loop (EC2), as it has been shown that the EC2 is very
important for D2 receptor agonist binding
[54] and receptor acti-
vation.
[53]
The combined pharmacophore and receptor modeling ap-
proach enabled optimal use of all relevant structure–activity,
mutation, protein structure, and sequence data, and also pro-
vided a strong basis for the interpretation of the requirements
for dopamine D2 receptor agonism based on what is known in
the field to date. The combined approach also makes it easier
to highlight weaknesses in each of the modeling methodolo-
gies and in the quality of the obtained models.
The new strategy can be highly useful in less well-character-
ized systems to explore ligand–receptor interactions and to
guide the construction of each model to make it more credible
for further analysis. A key ingredient to more accurate models
is the diversity of the ligand set used for the construction of
the pharmacophore model.
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